

# Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H1 2018

https://marketpublishers.com/r/GA92DB721F8EN.html

Date: April 2018

Pages: 51

Price: US\$ 3,500.00 (Single User License)

ID: GA92DB721F8EN

## **Abstracts**

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H1 2018

#### SUMMARY

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration.

The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 3 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Diabetes, Obesity and Type 1 Diabetes (Juvenile Diabetes).

The latest report Glucokinase - Pipeline Review, H1 2018, outlays comprehensive



information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC



2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

#### **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



## **Contents**

Introduction

Global Markets Direct Report Coverage

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies

Involved in Therapeutics Development

Amgen Inc

Eli Lilly and Co

Ligand Pharmaceuticals Inc

Merck & Co Inc

Poxel SA

Teijin Pharma Ltd

vTv Therapeutics Inc

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles

AM-9514 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

dorzagliatin - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug

**Profile** 

**Product Description** 

Mechanism Of Action



**R&D Progress** 

LY-2608204 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecules to Activate Glucokinase for Diabetes - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

TMG-123 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

TTP-399 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued

**Products** 

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product

**Development Milestones** 

Featured News & Press Releases

Mar 22, 2018: vTv Therapeutics Announces Completion of Phase 1b Study Evaluating

TTP399 for the Treatment of Type 1 Diabetes

Nov 08, 2017: vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the

Treatment of Type1 Diabetes



Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug

Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results from Phase 2B Study of Glucokinase Activator TTP399 in Type 2 Diabetes

Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes

Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial

Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes

Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics

Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013

**Appendix** 

Methodology

Coverage

Secondary Research

**Primary Research** 

**Expert Panel Validation** 

Contact Us

Disclaimer



## **List Of Tables**

#### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by Poxel SA, H1 2018

Pipeline by Teijin Pharma Ltd, H1 2018

Pipeline by vTv Therapeutics Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

#### **COMPANIES MENTIONED**

Amgen Inc
Eli Lilly and Co
Ligand Pharmaceuticals Inc
Merck & Co Inc
Poxel SA
Teijin Pharma Ltd
vTv Therapeutics Inc



#### I would like to order

Product name: Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H1

2018

Product link: <a href="https://marketpublishers.com/r/GA92DB721F8EN.html">https://marketpublishers.com/r/GA92DB721F8EN.html</a>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/GA92DB721F8EN.html">https://marketpublishers.com/r/GA92DB721F8EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

